TXG 10x Genomics, Inc.
Company Analysis
Latest News
🟢 10x Genomics is trading 4.84% up
10x Genomics is trading 4.84% up at $102.47 as of 9:36 a.m. EST on October 6, 2026, with no specific catalyst identified. - No fresh company announcement for...
🟢 10x Genomics is trading 4.3% up today as technology and growth stocks advance
10x Genomics is trading at $97.52, up 4.30%, amid supportive broader-market sentiment; no clear company-specific catalyst was identified. - At 2:25 p.m. EST...
🟢 10x Genomics is trading 5% up today amid broader market gains
10x Genomics is trading at $93.39, up 5.22%, with no clear company-specific catalyst identified for the move. - No 10x Genomics-specific catalyst dated October...
🟢 10x Genomics is trading 4.37% up today as Atera orders top 2026 shipment expectations
10x Genomics is trading at $93.97, up 4.37%, amid strong orders for its newly launched Atera system. - Commercial Atera shipments began September 29; booked...
10x Genomics Starts Atera Shipments as Orders Top 2026 Expectations
10x Genomics has begun the first commercial shipments of its Atera instrument, a spatial biology platform introduced in April 2026. Booked orders have already...
🟢 10x Genomics is trading 4.03% up, as patent-win momentum continues
10x Genomics is trading at $89.16, up 4.03%, as company-specific momentum extends its recent rally. - Reports linked the September 24 surge to a favorable...
🟢 10x Genomics is trading 10.14% up today with no confirmed catalyst
10x Genomics is trading 10.14% higher at $83.29, with no confirmed company-specific catalyst identified for September 24. - The rebound follows a 6.29%...
🟢 10x Genomics is trading 7.2% up today
10x Genomics is trading at $81.03, up 7.15%, with no confirmed catalyst for the rebound. - No clear company-specific announcement was reported on September...
🔴 10x Genomics is trading 4.18% down today as inflation and rate concerns pressure growth stocks
10x Genomics is trading 4.18% down at $77.33 as renewed inflation and interest-rate concerns weigh on U.S. equities. - The Nasdaq Composite is down 1.05%,...
🟢 10x Genomics rises 4.1% — Biotech Sector Rallies on Major AI Collaboration Deal and Positive Clinical News
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is trading higher, driven by a...
🟢 10x Genomics is trading 4.3% up today amid technology and AI-linked stock gains
10x Genomics is trading at $79.90, up +4.31%, alongside a stronger risk-on session led by technology and AI-linked stocks. - The S&P 500 is up 0.80% and the...
🟢 10x Genomics rises 5.8% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🟢 10x Genomics is trading 6.1% up today
10x Genomics is trading 6.1% higher at $74.36, with no clear company-specific catalyst identified for September 15, 2026. - Recent coverage highlights an...
🔴 10x Genomics is trading 4.4% down today amid broad technology and risk-asset selling
10x Genomics is trading 4.4% down at $65.57 as broad technology and risk-asset selling pressured the market on September 14, 2026. - The Nasdaq Composite is...
🟢 10x Genomics is trading 5% up today after announcing Lunit AI-pathology collaboration
10x Genomics is trading 4.73% up at $69.52 after announcing a collaboration with Lunit to combine AI-powered pathology analysis with spatial molecular data for...
10x Genomics Target Triples to $68, Following Strong Q2 Earnings Beat
UBS increased its price target for 10x Genomics, Inc. to $68. The new valuation represents a significant rise from the previous $20 target. The firm...
🟢 10x Genomics is trading 5% up today after T. Rowe Price disclosed an 11.7% stake
10x Genomics is trading at $65.84, up +5.09% after T. Rowe Price Associates disclosed an 11.7% stake. - The ownership disclosure was confirmed through an SEC...
10x Genomics Attracts T. Rowe Price Stake, Following 350% Stock Surge
T. Rowe Price Associates, Inc. acquired an 11.7% stake in 10x Genomics, Inc. The institutional investor now beneficially owns 14,044,020 Class A common...
🟢 10x Genomics is trading 4.47% up today after RBC initiated coverage with a Sector Perform rating
10x Genomics is trading 4.47% up at $62.66 after Royal Bank of Canada initiated coverage of its shares with a Sector Perform rating, equivalent to Hold. RBC...
10x Genomics Upgraded to 'Hold' by Royal Bank of Canada
Royal Bank of Canada upgraded 10x Genomics to "Hold." The broader analyst consensus for 10x Genomics remains "Hold." Analysts set an average price target of...